Research Papers:

Management of salivary gland carcinomas - a review

Xiaoli Wang, Yijun Luo, Minghuan Li, Hongjiang Yan, Mingping Sun and Tingyong Fan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:3946-3956. https://doi.org/10.18632/oncotarget.13952

Metrics: PDF 3232 views  |   HTML 3556 views  |   ?  


Xiaoli Wang1,2, Yijun Luo1,2, Minghuan Li2, Hongjiang Yan2, Mingping Sun2 and Tingyong Fan2

1 School of Medical and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China

2 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Correspondence to:

Tingyong Fan, email:

Keywords: salivary gland cancers, adenoid cystic carcinoma, elective neck dissection, chemotherapy, targeted therapy

Received: June 16, 2016 Accepted: December 08, 2016 Published: December 15, 2016


Salivary gland carcinomas are a heterogeneous group of tumors with many histological subtypes which occur in both major and minor salivary glands. However, they have a relatively low of incidence. Their rarity limits study size and the ability to perform phase III trials. Therefore, to date, the entire management is usually varied. Certain published studies have paid more attention to the systemic therapy in the management of metastatic or locally recurrent salivary gland cancer, while little effort has been made to study the entire management for this lesions. Although results of treatment for patients with salivary gland carcinoma have improved in recent years, the treatment of salivary gland cancers is still not standardized. And some patients who haven’t received optimal treatment strategies had a reduced survival. In this review, the topics covered include surgery and radiotherapy, selective neck dissection, chemotherapy, and targeted therapy, which aimed to summarize the optimal management approaches and to develop recommendations for managing this lesions. For these rare cancers, there is also a need for a determined, coordinated effort to conduct high-quality clinical trials.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13952